Lexaria Advances Human Nicotine Study with IRB Approval; Dosing to Commence Imminently
Global innovator in drug delivery, Lexaria Bioscience (Nasdaq: LEXX) has received Independent Board Review approval for its human nicotine study.
The study will compare the company’s DehydraTECH-nicotine pouch performance to existing leading brands ON! and Zyn.
The oral nicotine pouch category is one of the fastest growing segments of the nicotine industry. The global oral nicotine pouch is expected to reach $21.84 billion in 2027.
- The study is a 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study.
- Lexaria has previously demonstrated in an animal study that nicotine oral pouches using DehydraTECH technology were 10x to 20x faster in reaching peak delivery of nicotine to bloodstream than controls.
- In March 2022, Lexaria received its first patent granted to use DehydraTECH to more efficiently deliver nicotine through buccal tissue absorption.
Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to currently sold brands.